|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF275 |
Gene summary for ZNF275 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF275 | Gene ID | 10838 |
| Gene name | zinc finger protein 275 | |
| Gene Alias | ZNF275 | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A6NFS0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10838 | ZNF275 | HCC1_Meng | Human | Liver | HCC | 5.33e-39 | 8.40e-02 | 0.0246 |
| 10838 | ZNF275 | HCC2_Meng | Human | Liver | HCC | 1.18e-15 | 1.39e-01 | 0.0107 |
| 10838 | ZNF275 | HCC2 | Human | Liver | HCC | 7.25e-05 | 3.01e+00 | 0.5341 |
| 10838 | ZNF275 | S027 | Human | Liver | HCC | 8.20e-08 | 8.23e-01 | 0.2446 |
| 10838 | ZNF275 | S028 | Human | Liver | HCC | 8.54e-23 | 8.12e-01 | 0.2503 |
| 10838 | ZNF275 | S029 | Human | Liver | HCC | 3.50e-19 | 8.25e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF275 | DC | Breast | ADJ | PARN,ASB2,MAPKAPK3, etc. | 3.05e-02 |  |
| ZNF275 | INMON | Breast | ADJ | PARN,ASB2,MAPKAPK3, etc. | 4.47e-02 | |
| ZNF275 | MAST | Breast | DCIS | PARN,ASB2,MAPKAPK3, etc. | 1.47e-02 |  |
| ZNF275 | MAST | Breast | Healthy | PARN,ASB2,MAPKAPK3, etc. | 2.63e-02 |  |
| ZNF275 | CD8TEX | Breast | Healthy | PARN,ASB2,MAPKAPK3, etc. | 5.85e-03 | |
| ZNF275 | NK | Breast | Precancer | PARN,ASB2,MAPKAPK3, etc. | 2.28e-02 |  |
| ZNF275 | CD4TN | Breast | Precancer | PARN,ASB2,MAPKAPK3, etc. | 1.71e-03 | |
| ZNF275 | DC | Colorectum | ADJ | MTX3,UBE2J1,AMY2B, etc. | 6.40e-02 |  |
| ZNF275 | MON | Colorectum | FAP | MTX3,UBE2J1,AMY2B, etc. | 2.09e-02 |  |
| ZNF275 | MAST | Colorectum | FAP | MTX3,UBE2J1,AMY2B, etc. | 2.59e-02 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 3 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF275 | SNV | Missense_Mutation | novel | c.770G>A | p.Arg257His | p.R257H | protein_coding | tolerated(0.08) | benign(0.015) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF275 | SNV | Missense_Mutation | c.331C>T | p.Arg111Trp | p.R111W | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ZNF275 | SNV | Missense_Mutation | rs782151498 | c.647N>A | p.Arg216Gln | p.R216Q | protein_coding | tolerated(0.05) | benign(0.014) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF275 | SNV | Missense_Mutation | novel | c.551A>G | p.Glu184Gly | p.E184G | protein_coding | tolerated(0.06) | benign(0.022) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF275 | SNV | Missense_Mutation | novel | c.964G>A | p.Ala322Thr | p.A322T | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | |
| ZNF275 | SNV | Missense_Mutation | novel | c.640N>C | p.Cys214Arg | p.C214R | protein_coding | deleterious(0) | benign(0.31) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| ZNF275 | SNV | Missense_Mutation | novel | c.863N>A | p.Ser288Asn | p.S288N | protein_coding | tolerated(0.06) | possibly_damaging(0.462) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| ZNF275 | SNV | Missense_Mutation | novel | c.89T>G | p.Leu30Arg | p.L30R | protein_coding | tolerated(0.18) | possibly_damaging(0.505) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF275 | SNV | Missense_Mutation | rs781856747 | c.544N>A | p.Glu182Lys | p.E182K | protein_coding | tolerated(0.06) | benign(0.013) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF275 | SNV | Missense_Mutation | novel | c.160A>G | p.Met54Val | p.M54V | protein_coding | tolerated(0.4) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |